OneMedNet Corp (NASDAQ:ONMD) has seen significant insider activity following a substantial equity acquisition by one of its key executives. Jeffrey Yu, who maintains roles as the company's Chief Medical Officer, a director, and a ten percent shareholder, executed a major transaction on April 1, 2026, that substantially bolsters his position in the organization.
According to regulatory filings, Mr. Yu participated in a subscription agreement with OneMedNet Corp for an investment totaling approximately $749,999. This investment resulted in the acquisition of 903,614 shares of common stock. The transaction price was set at $0.83 per share, a valuation derived from the volume-weighted average price observed during the ten trading days immediately preceding the purchase date.
In addition to this direct investment, Mr. Yu was issued 219,429 additional shares of common stock on the same day. These shares were valued at $0.83 per share, representing a total value of approximately $182,126. This issuance served as a replacement for prior cash compensation that was owed to him. Similar to the subscription agreement, the valuation for these shares was based on the volume-weighted average price over the ten trading days leading up to the issuance.
Updated Ownership Structure
Following these recent transactions, Mr. Yu's direct holdings in OneMedNet common stock have risen to 8,449,266 shares. The filings also note that an additional 1,311,970 shares are held indirectly through a trust established for his children. However, Mr. Yu has disclaimed beneficial ownership of these indirect holdings, stating that the trust is managed by an independent trustee and that he retains no investment control over those assets. These details were formally disclosed in a Form 4 filing with the Securities and Exchange Commission on April 24, 2026.
Operational and Financial Context
The insider activity occurs against a backdrop of notable shifts in OneMedNet's financial performance and strategic direction. The company reported a substantial revenue increase for the year 2025, reaching $1.25 million compared to $292,000 in 2024, representing a 329% jump. Specifically, the fourth quarter saw revenues of $890,000. On the liability side, the company managed to reduce its total liabilities from $19.7 million down to $5.1 million.
On the operational front, OneMedNet has been aggressively expanding its data ecosystem. The company recently entered into a partnership with Inka Health to integrate its iRWD platform with oncology data, which will support Onco-Innovations' PNKP Inhibitor Technology. Furthermore, a collaboration with ViuHealth was established to incorporate autoimmune disease data, including treatment outcomes and patient journeys, into the platform. The company has also advanced the commercial phase of its Real-World Data Platform using Palantir Foundry, leading to multi-year subscription agreements and increased use within the AI health and life sciences sectors.
Market Position and Performance Indicators
While the company shows growth in revenue and strategic partnerships, certain financial metrics present a complex picture. The stock is currently trading at $0.89, which is a recovery from its 52-week low of $0.31, though it remains down 62% over the last six months. OneMedNet holds a market capitalization of $46.39 million and maintains a current ratio of 0.43, which points toward liquidity pressures within the firm.
Additionally, the company faces a regulatory hurdle regarding its listing status. The Nasdaq Listing Qualifications Department has issued a notice because the stock failed to meet the minimum bid price requirement of $1.00. OneMedNet is required to maintain a minimum bid price of at least $1.00 for ten consecutive business days by October 12, 2026, to regain compliance.